Troleandomycin (TAO)

01/01/1992 - "To investigate the efficacy of magnetic resonance imaging (MRI) in the assessment of thyroid-associated ophthalmopathy (TAO), 51 patients with TAO were evaluated by ophthalmologic examinations and MRI at 0.5 T. "
09/01/2015 - "This study aimed to screen potential genes related to thyroid-associated ophthalmopathy (TAO) and get a further understanding about the pathogenesis of this disease. "
05/01/2014 - "Previous studies have extensively investigated the pathophysiology, genetics, and lifestyle risk factors of thyroid-associated ophthalmopathy (TAO). "
01/01/2014 - "The aim of the present study was to identify a new candidate anti-inflammatory compound for use in the active stage of thyroid-associated ophthalmopathy (TAO). "
10/01/2010 - "Patient who developed or got worse of thyroid-associated ophthalmopathy (TAO) at any time point during the 4-year study period (TAO group) had lower QoL when no respect was paid to the mode of treatment. "

01/01/2001 - "troleandomycin is a compound that is established as an effective antibiotic but may also have non antibacterial actions that may be useful in the treatment of asthma. "
12/01/1980 - "Efficacy of troleandomycin in outpatients with severe, corticosteroid-dependent asthma."
11/01/1993 - "This study confirms that treatment with MP and TAO has a beneficial effect in a subgroup of severely steroid-dependent asthma patients."
01/01/2001 - "There is insufficient evidence to support the use of troleandomycin in the treatment of steroid dependent asthma."
01/01/2001 - "Troleandomycin as an oral corticosteroid steroid sparing agent in stable asthma."

01/01/1983 - "The long-term follow-up of 19 cases with thromboangitis obliterans (TAO) (20 limbs) revealed excellent results in 62%, good results in 19% and poor results in 19%. "
10/01/2014 - "The aim of this study was to find a disease-specific activity score for Thromboangiitis obliterans (TAO). "
01/01/2014 - "Buerger's disease or thromboangiitis obliterans (TAO) seems to be common in IR Iran, The present study aimed to evaluate an Iranian population with Buerger's disease in order to suggest a diagnostic criterion for Buerger's disease based on the most frequent findings and to compare it with Papa diagnostic criteria. "
01/01/2014 - "The aim of this study was to investigate the impact of thromboangiitis obliterans (TAO) sera on activation of primary cultures of human umbilical vein endothelial cells (HUVECs) as a model for vascular endothelial cells. "
05/01/1998 - "To date there have been no clinical studies providing data on which to base a long-term medical and social prognosis of thromboangiitis obliterans (TAO). "

12/01/1969 - "However, this prediction was not fulfilled in these studies of experimental infections in monkeys wherein triacetyloleandomycin was a very effective antimicrobial agent."
02/01/1960 - "A study of triacetyloleandomycin in general infections of institutionalized patients."
03/01/1959 - "A clinical study of triacetyloleandomycin in urological infections."
12/01/1999 - "Between November 1995 and January 1996, one larger-scale outbreak of Shigella sonnei infection occurred in the area of Tao-Yuan, Taiwan. "
02/01/1976 - "Triacetyloleandomycin in streptococcal throat infections. "

01/01/1990 - "In patients with TAO mean (+/- SE) IOP was significantly greater than that in patients with Graves' disease without apparent eye involvement for the primary position and for all gaze positions. "
12/01/2008 - "The aim of this study, therefore, was to determine the prevalence, risk factors, and clinical features of TAO in a cohort of multiethnic Malaysian patients with Graves' disease (GD). "
11/01/2007 - "The study was performed in 40 Graves disease, hyperthyroid and euthyroid patients with a clinically active form of TAO. "
11/01/2006 - "The aim of the study was to correlate the concentration of urinecotinine (marker of tobacco smoking) in Graves' disease patients with TAO with points received on the Fagerström questionnaire. "
01/01/2004 - "The aim of this study is to evaluate serum concentrations of sVCAM-1 in patients with Graves' disease (GD) and thyroid associated orbitopathy (TAO). "